Stock listing

ASX:OIL Optiscan Imaging Limited Share Price

Home listing (ASX) of Optiscan Imaging Limited

Follow Optiscan Imaging Limited into a list and get an email when it puts out news.

Share price · ASX:OIL

$0.12 AUD -0.02 (-14.3%)

Close on Nov 20, 2026

Past year +14.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.10 – $0.125 AUDNov 20, 2026
Volume
862,098 sharesNov 20, 2026
Market cap
$125.5M AUDAt the close on Nov 20, 2026 · price × 1.05B shares outstanding
52-week range
$0.08 – $0.20 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$27,885 AUDMedian day 119,167 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Optiscan Imaging Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:OIL · Home$0.12 AUD-0.02 (-14.3%)862,098$0.125$0.125$0.10$0.14Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:OIL · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.12-0.02-14.3%$0.125$0.125$0.10862,098
$0.14-0.005-3.4%$0.15$0.15$0.135307,822
$0.145-0.01-6.5%$0.15$0.155$0.14555,086
$0.1550.000.0%$0.155$0.155$0.14590,549
$0.155-0.003-1.6%$0.155$0.16$0.15543,104
$0.158+0.003+1.6%$0.155$0.16$0.15545,649
$0.155-0.005-3.1%$0.155$0.155$0.155506
$0.160.000.0%$0.16$0.165$0.155123,300
$0.16-0.005-3.0%$0.16$0.17$0.155325,639
$0.165+0.01+6.5%$0.155$0.17$0.155199,549
$0.155+0.005+3.3%$0.16$0.16$0.15544,066
$0.15-0.01-6.3%$0.155$0.16$0.1581,181
$0.16+0.01+6.7%$0.153$0.16$0.15119,167
$0.15-0.005-3.2%$0.15$0.15$0.14163,167
$0.155+0.005+3.3%$0.15$0.155$0.145200,756
$0.15+0.005+3.4%$0.155$0.16$0.1546,395
$0.145+0.005+3.6%$0.14$0.145$0.1422,023
$0.14-0.015-9.7%$0.16$0.16$0.1457,321
$0.155-0.005-3.1%$0.155$0.16$0.153209,042
$0.16+0.005+3.2%$0.16$0.165$0.1659,261
$0.1550.000.0%$0.165$0.17$0.15560,350
$0.1550.000.0%$0.155$0.16$0.1547,973
$0.1550.000.0%$0.16$0.16$0.15510,815
$0.155-0.01-6.1%$0.165$0.165$0.155176,746
$0.165+0.025+17.9%$0.145$0.165$0.145711,876
$0.14-0.015-9.7%$0.155$0.16$0.14369,608
$0.155-0.005-3.1%$0.16$0.16$0.145106,948
$0.16-0.005-3.0%$0.17$0.175$0.15650,244
$0.165+0.005+3.1%$0.16$0.17$0.16225,223
$0.16-0.015-8.6%$0.17$0.17$0.155220,746
$0.175-0.005-2.8%$0.17$0.18$0.17152,245
$0.180.000.0%$0.18$0.185$0.17317,813
$0.18+0.01+5.9%$0.177$0.195$0.177346,461
$0.17+0.005+3.0%$0.17$0.195$0.17439,779
$0.165+0.005+3.1%$0.16$0.17$0.16341,322
$0.16+0.025+18.5%$0.135$0.16$0.13575,151
$0.1350.000.0%$0.13$0.135$0.1358,876
$0.1350.000.0%$0.137$0.14$0.13119,543
$0.135+0.005+3.8%$0.135$0.14$0.13168,759
$0.13-0.01-7.1%$0.14$0.14$0.1378,099
$0.14+0.005+3.7%$0.135$0.14$0.13529,799
$0.135-0.005-3.6%$0.145$0.145$0.13520,385
$0.140.000.0%$0.14$0.145$0.1444,135
$0.14-0.01-6.7%$0.15$0.15$0.1471,693
$0.15+0.005+3.4%$0.145$0.15$0.1413,897
$0.1450.000.0%$0.145$0.155$0.1440,342
$0.145-0.015-9.4%$0.15$0.15$0.1418,536
$0.16+0.01+6.7%$0.16$0.16$0.14141,745
$0.15-0.005-3.2%$0.155$0.155$0.135463,843
$0.155+0.005+3.3%$0.15$0.165$0.1561,808
$0.150.000.0%$0.15$0.15$0.1455,854
$0.150.000.0%$0.15$0.16$0.14376,399
$0.150.000.0%$0.15$0.155$0.1533,955
$0.15+0.005+3.4%$0.145$0.155$0.14523,793
$0.145-0.015-9.4%$0.16$0.16$0.14549,008
$0.16+0.01+6.7%$0.15$0.16$0.135475,659
$0.15-0.005-3.2%$0.155$0.155$0.14556,275
$0.1550.000.0%$0.155$0.155$0.14353,846
$0.1550.000.0%$0.16$0.16$0.15153,510
$0.155-0.01-6.1%$0.165$0.165$0.15311,958
$0.1650.000.0%$0.165$0.167$0.16121,374
$0.165-0.01-5.7%$0.17$0.18$0.165123,297
$0.175+0.005+2.9%$0.17$0.175$0.165359,221
$0.170.000.0%$0.17$0.17$0.1657,039
$0.17+0.01+6.3%$0.16$0.17$0.1572,524

Splits

1 split · ASX:OIL · every price before a split is adjusted for it

DayRatioWhat
99-for-97Split
Ticker
ASX:OIL
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Optiscan Imaging Limited news

Optiscan Imaging Limited on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
32 in the last 12 months · 198 in all · newest Nov 19, 2026 · oldest 2016
Decks
38 decks · latest Nov 17, 2026

Where Optiscan Imaging Limited is listed

ListingExchangeCountryCurrency
ASX:OIL · Home listing · This pageASXAustraliaAUD
OTC:OILAFOTCUnited StatesUSD

Valuation

EV/sales 251× against a median of 1.8×: the highest of 9 Medical devices & supplies companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$112.5M AUD
P/E
Loss
EV/sales
251×
EV/EBITDA
Negative EBITDA
Price/book
6.6×
Gross margin
−176.1%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Optiscan Imaging Limited · ASX:OILUS$83.05MUS$74.44Mn/a251×n/a6.6×n/a0.1×n/a
SciVision Biotech Inc. · TWSE:1786US$88.98MUS$76.24M16.5×2.8×10.7×1.6×20.0%0.3×n/a
Owlet, Inc. · NYSE:OWLTUS$87.58MUS$66.96Mn/a0.6×n/a3.3×−10.2%0.4×2.11
EMvision Medical Devices Ltd. · ASX:EMVUS$87.37MUS$78.30Mn/an/an/a8.4×n/a0.2×n/a
Maxigen Biotech Inc. · TWSE:1783US$86.53MUS$59.38M9.8×2.3×6.7×1.9×34.8%0.1×n/a
Viromed Medical AG · XETR:VMEUS$83.96MUS$83.66M127×15.0×n/a8.1×11.9%0.0×n/a
ICARES Medicus Inc · TPEX:6612US$83.86MUS$61.27M29.6×1.7×7.3×1.5×7.7%0.0×n/a
Nyxoah SA · EURONEXT:NYXHUS$83.60MUS$6.53Mn/a0.3×n/a0.9×−443.2%0.3×n/a
EBR Systems, Inc. · ASX:EBRUS$79.78MUS$36.17Mn/an/an/a1.0×n/a0.5×n/a
DIO Corporation · KRX:039840US$78.78MUS$59.85M4.8×0.5×3.4×0.6×12.7%0.1×n/a
Zomedica Corp. · OTC:ZOMDFUS$78.49MUS$71.21Mn/a1.8×n/a0.8×−41.3%0.0×0.10
Median of the othersUS$83.91MUS$64.12M16.5×1.8×7.0×1.6×9.8%0.2×1.11

Team and board

Officers

OfficerRole
Camile FarahChief Executive Officer
Darius OoiChief Financial Officer
Elissa HansenCompany Secretary
Jessica WardDirector of Clinical and Regulatory Affairs
Robert SayeghDirector of Strategy & Portfolio Integration
Sanchitha FernandoChief Technology Officer

Board

DirectorRole
Robert CookeNon-Executive Chairman
Karen BorgNon-Executive Director
Ron SongNon-Executive Director
Russell LowNon-Executive Director
Sean GardinerNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 29, 2025
Q2 2025Feb 27, 20250.0%
Q2 2023Feb 27, 2023 · After close−4.1%
Q4 2022Aug 31, 2022 · After close0.0%
Q2 2022Feb 24, 2022+12.5%
Q4 2021Aug 29, 20210.0%
Q2 2021Feb 25, 2021+6.3%

Open Events

Decks

DeckKindSlidesDate
Bell Potter Healthcare Conference (November 2026)Conference11 slidesNov 17, 2026
Investor Presentation (December 2025)Investor deck37 slidesDec 4, 2025
Shareholder Meeting (November 2025)Shareholder meeting40 slidesNov 14, 2025
ASX SMIDcaps Conference, Sydney 2025Conference22 slidesSep 24, 2025
Corporate Update (April 2025)Corporate update26 slidesApr 10, 2025
TSN ASX Gems Conference (March 2025)Conference16 slidesMar 28, 2025
Shareholder Meeting (November 2024)Shareholder meeting26 slidesNov 21, 2024
Non-Deal Roadshow (July 2024)Roadshow29 slidesJul 1, 2024
Investor Presentation (May 2024)Investor deck25 slidesMay 16, 2024
Shareholder Meeting (November 2023)Shareholder meeting34 slidesNov 23, 2023
All 38 decks
DeckKindSlidesDate
Shareholder Meeting (November 2022)Shareholder meeting42 slidesNov 24, 2022
Shareholder Meeting (January 2022)Shareholder meeting35 slidesJan 20, 2022
FY2021 Earnings PresentationEarnings23 slidesAug 30, 2021
Shareholder Meeting (November 2020)Shareholder meeting18 slidesNov 26, 2020
Australia Biotech Invest & Partnering 2020Conference16 slidesOct 29, 2020
Investor Presentation (August 2020)Investor deck21 slidesAug 25, 2020
Austrade virtual China conference with AstraZeneca, Wuxi iCampus and CSIRO, July 2020Conference13 slidesJul 24, 2020
Zhejiang Provincial Science and Technology Cooperation Center Conference (July 2020)Conference17 slidesJul 3, 2020
Investor Presentation (February 2020)Investor deck15 slidesFeb 28, 2020
Shareholder Meeting (November 2019)Shareholder meeting24 slidesNov 28, 2019
AusBiotech Conference 2019Conference13 slidesOct 31, 2019
Investor Presentation (June 2019)Investor deck18 slidesJun 14, 2019
Investor Presentation (April 2019)Investor deck17 slidesApr 29, 2019
Investor Presentation (March 2019)Investor deck20 slidesMar 14, 2019
Corporate Update (March 2019)Corporate update19 slidesMar 14, 2019
Shareholder Meeting (November 2018)Shareholder meeting17 slidesNovember 2018
Shareholder Meeting (November 2017)Shareholder meeting14 slidesNov 24, 2017
Investor Presentation (September 2017)Investor deck18 slidesSeptember 2017
Investor Presentation (July 2017)Investor deck41 slidesJul 3, 2017
Shareholder Meeting (November 2012)Shareholder meeting26 slidesNov 20, 2012
Australian Life Science Investment Summit 2012Conference20 slidesNov 2, 2012
Investor Presentation (September 2012)Investor deck18 slidesSep 17, 2012
Australian Bio-Investment Forum July 2007Conference21 slidesJul 10, 2007
Shareholder Meeting (November 2006)Shareholder meeting15 slidesNov 8, 2006
Investor Presentation (October 2003)Investor deck22 slidesOct 21, 2003
Shareholder Meeting (November 2002)Shareholder meeting26 slidesNov 13, 2002
Shareholder Meeting (November 2001)Shareholder meeting30 slidesNov 8, 2001
Investor PresentationInvestor deck20 slides

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue448.8K3.72M1.16M1.68M1.01M889.5K1.19M1.32M2.97M1.33M
Cost of revenue1.24M472.1K526.2K1.17M2.67M1.28M640.6K1.11M1.25M506.5K
Gross profit-790.2K3.25M629.4K514.8K-1.66M-385.9K550.1K216.3K1.72M826.8K
Research and development6.28M5.09M3.90M2.44M2.17M1.67M1.61M703.8K1.97M2.21M
Selling, general and administrative4.18M4.17M4.35M3.60M1.65M1.24M984.0K1.16M1.63M1.50M
Operating income-10.6M-6.17M-8.41M-5.29M-5.47M-3.72M-2.38M-2.35M-2.00M-3.88M
Depreciation and amortization322.7K429.6K567.3K378.8K240.6K238.3K237.2K122.1K88.6K41.8K
EBITDA-10.3M-5.74M-7.85M-4.91M-5.23M-3.48M-2.15M-2.23M-1.92M-3.84M
Interest expense81.5K25.8K23.7K32.3K32.2K56.3K63.9K63.9K42.5K72.5K
Income before tax-9.37M-6.29M-6.06M-5.09M-5.17M-2.97M-2.47M-2.34M-2.04M-2.94M
Income tax-2.39M20.3K-994.7K-737.6K-941.8K-847.3K-701.2K-230.9K-781.8K-980.3K
Net income-6.99M-6.31M-6.06M-4.35M-4.23M-2.13M-1.77M-2.34M-2.04M-2.94M
Earnings per share, basic-0.01-0.01-0.01-0.01-0.01-0.00-0.00-0.01-0.00-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents14.4M4.55M6.10M875.4K4.53M8.44M526.4K1.75M1.56M700.7K
Short-term investments5.13M53.6K53.6K0
Receivables2.85M316.6K1.57M975.9K1.41M1.24M758.4K150.3K346.5K230.4K
Inventory2.35M1.67M2.00M1.44M1.27M1.16M1.15M1.16M885.6K495.9K
Current assets20.4M8.86M15.1M3.65M7.32M11.0M2.51M3.36M3.72M2.51M
Property, plant and equipment1.69M407.3K575.7K609.0K675.2K882.6K227.9K345.4K159.1K
Total assets22.0M10.6M15.6M4.67M7.98M11.7M3.44M3.64M4.13M2.67M
Accounts payable682.5K373.6K539.9K524.5K303.2K396.6K336.8K224.4K326.7K566.8K
Current liabilities1.88M1.51M1.75M1.42M1.00M973.4K1.24M818.4K915.2K994.8K
Total debt1.34M1.48M220.9K412.3K570.9K668.0K1.16M200.0K
Total liabilities3.08M2.84M1.76M1.63M1.39M1.48M1.90M820.6K928.7K1.00M
Shareholders' equity18.9M7.71M13.9M3.04M6.59M10.2M1.55M2.82M3.20M1.67M
Shares outstanding996.1M835.3M822.9M623.3M631.1M583.2M484.1M442.6M414.9M333.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-7.10M-6.21M-5.74M-3.15M-3.83M-2.13M-1.40M-1.42M-2.32M-3.41M
Capital spending-256.0K-93.1K-87.4K-126.9K-124.1K-30.9K-20.2K-4.51K-290.5K-181.2K
Free cash flow-7.36M-6.31M-5.83M-3.28M-3.96M-2.16M-1.42M-1.43M-2.61M-3.59M
Cash from investing-256.0K5.05M-5.23M-126.9K-124.1K-30.9K-20.2K5.49K-353.1K-181.2K
Cash from financing17.2M-381.9K16.2M-374.5K44.6K10.1M190.7K1.61M3.54M3.34M
Dividends paid-155.6K-9.82M-351.5K-3.02M
Share buybacks-179.8K0-104.5K41.0K-200.2K-423.3K-4.03K-94.8K-298.7K-289.9K
Change in cash9.80M-1.55M5.23M-3.65M-3.91M7.92M-1.23M189.9K861.8K-254.1K

Open Financials

Filings

FilingDateTypeFiled with
Extension of Time to Hold Annual General MeetingNov 19, 2026Meeting noticeASX
Bell Potter Healthcare Conference PresentationNov 16, 2026Operations updateASX
Optiscan Strengthens Board with Appointment of Russell LowNov 4, 2026Management or board changeASX
Notification of cessation of securities - OILNov 3, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Optiscan Lodges U.S. FDA 510(k) Submission for InVueOct 4, 2026Operations updateASX
Optiscan Lodges U.S. FDA 510(k) Submission for InFormOct 1, 2026Operations updateASX
Change of Director's Interest NoticeSep 15, 2026Ownership change noticeASX
Notification of cessation of securities - OILSep 15, 2026FinancingASX
All 194 filings
FilingDateTypeFiled with
Application for quotation of securities - OILSep 15, 2026FinancingASX
Significant Milestone Reached in ACL Digital Pathology StudySep 9, 2026Operations updateASX
Change of Director's Interest NoticeSep 9, 2026Ownership change noticeASX
Application for quotation of securities - OILSep 9, 2026FinancingASX
Application for quotation of securities - OILSep 8, 2026FinancingASX
Change of Director's Interest NoticeSep 8, 2026Ownership change noticeASX
Change of Director's Interest NoticeSep 8, 2026Ownership change noticeASX
Optiscan Initiates Head and Neck Cancer Study in the USAug 31, 2026Operations updateASX
Preliminary Final ReportAug 24, 2026ResultsASX
Appendix 4G & Corporate Governance StatementAug 24, 2026Other filingsASX
2026 Annual ReportAug 24, 2026Annual reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 30, 2026Quarterly reportASX
Optiscan Signs New Research Agreement for Breast StudyJul 21, 2026Operations updateASX
Head and Neck Study Progressing Ahead of ScheduleJul 20, 2026Operations updateASX
Optiscan Launches InSpecta Device for Veterinary MedicineJul 6, 2026Operations updateASX
Halfway Mark Reached in Optiscan Breast Cancer StudyJun 3, 2026Operations updateASX
Second Anniversary of Optiscan and Mayo Clinic AgreementMay 31, 2026Operations updateASX
Optiscan Receives $1.69m R&D Tax RefundMay 19, 2026ResultsASX
Optiscan Submits InSpecta FDA DossierMar 30, 2026Operations updateASX
Appendix 4DFeb 24, 2026Interim reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 29, 2026Quarterly reportASX
Optiscan Initiates Head & Neck Cancer Imaging StudyDec 2, 2025Operations updateASX
Optiscan Partners with ACL to Advance Digital PathologyNov 10, 2025Operations updateASX
Appendix 4E - Preliminary Final ReportAug 29, 2025ResultsASX
Entitlement Issue ProspectusAug 27, 2025FinancingASX
Optiscan Launches Entitlement Offer to Raise $17.75mAug 27, 2025FinancingASX
Optiscan Initiates Breast Cancer Study in MelbourneJun 30, 2025Other filingsASX
Optiscan Signs Agreement with Long Grove PharmaceuticalsJun 22, 2025Acquisition or disposalASX
Optiscan Reveals InSpecta Device for Veterinary MedicineJun 9, 2025Operations updateASX
Optiscan Completes Cloud-based Telepathology Software MVPMay 26, 2025Other filingsASX
Robotic Surgery Collaboration with Mayo Clinic ProgressesMay 12, 2025Operations updateASX
Optiscan Reveals InForm Imaging Device for PathologyFeb 18, 2025Operations updateASX
Optiscan Initiates GI Study in Germany with First PrototypeFeb 2, 2025Operations updateASX
OIL December 2024 Quarterly Report and Appendix 4CJan 30, 2025Quarterly reportASX
Optiscan receives $1.775m R&D Tax RefundJan 30, 2025ResultsASX
OIL Managing Director's Presentation & Chair's AddressNov 21, 2024Other filingsASX
Optiscan Signs Research Agreement with Minnesota Vet CollegeNov 18, 2024Other filingsASX
Optiscan Signs Agreement with Monash to Progress GI ScopeNov 3, 2024Operations updateASX
OIL September 2024 Quarterly Report and Appendix 4COct 31, 2024Quarterly reportASX
Appendix 4E Preliminary Final ReportAug 30, 2024ResultsASX
Optiscan Signs MOU with University of MinnesotaAug 18, 2024Operations updateASX
OIL June 2024 Quarterly Report and Appendix 4CJul 31, 2024Quarterly reportASX
Optiscan Delivers Major Milestone in Telepathology PlatformJul 28, 2024Operations updateASX
Optiscan Receives Ethical Clearance for Breast Cancer StudyJul 14, 2024Operations updateASX
Optiscan 2024 Roadshow PresentationJun 30, 2024Other filingsASX
Optiscan Reveals InVue Imaging Device for Precision SurgeryJun 3, 2024Other filingsASX
Optiscan Webinar Investor PresentationMay 16, 2024Other filingsASX
Optiscan Signs Know-How Agreement with Mayo ClinicMay 12, 2024Operations updateASX
OIL March 2024 Quarterly Report and Appendix 4CApr 30, 2024Quarterly reportASX
Optiscan appoints US Clinical & Regulatory HeadsApr 2, 2024Management or board changeASX
OIL Appendix 4D and 31 December 2023 Half-year reportFeb 22, 2024Interim reportASX
Optiscan receives $3 million CRC-P Industry GrantFeb 13, 2024Operations updateASX
OIL December 2023 Quarterly Report and Appendix 4CJan 30, 2024Quarterly reportASX
Response to ASX Price QueryNov 14, 2023Explanation requestASX
OIL September 2023 Quarterly Report and Appendix 4COct 31, 2023Quarterly reportASX
Optiscan Correlates with Histology in Breast StudySep 19, 2023Operations updateASX
OIL Appendix 4E and June 2023 Annual ReportAug 30, 2023Annual reportASX
Optiscan Achieves Telepathology MilestoneAug 14, 2023Other filingsASX
OIL June 2023 Quarterly Report and Appendix 4CJul 28, 2023Quarterly reportASX
Entitlement Offer Results and Shortfall AnnouncementJul 12, 2023FinancingASX
Optiscan Entitlement Issue ProspectusMay 30, 2023FinancingASX
Optiscan Launches Entitlement Offer to Raise $16.7MMay 30, 2023FinancingASX
Trading HaltMay 25, 2023Trading halt or suspensionASX
OIL March 2023 Quarterly Report and Appendix 4CApr 28, 2023Quarterly reportASX
Optiscan Platform Highly Accurate for Oral Cancer DiagnosisMar 13, 2023Other filingsASX
Optiscan Intends to pursue De Novo Pathway for InVivageMar 2, 2023Other filingsASX
OIL Appendix 4D and 31 December 2022 Half-year reportFeb 27, 2023Interim reportASX
Optiscan partners with Prolucid to develop AI AlgorithmsJan 29, 2023Other filingsASX
OIL December 2022 Quarterly Report and Appendix 4CJan 27, 2023Quarterly reportASX
Optiscan Managing Director 2022 AGM PresentationNov 24, 2022Other filingsASX
OIL September 2022 Quarterly Report and Appendix 4COct 31, 2022Quarterly reportASX
Optiscan Imaging Acquires Intellectual PropertyOct 24, 2022Acquisition or disposalASX
Appendix 4E and 2022 Annual ReportAug 31, 2022Annual reportASX
Optiscan Submits FDA 510(k) Application for InVivage DeviceAug 21, 2022Other filingsASX
OIL June 2022 Quarterly Report and Appendix 4CJul 29, 2022Quarterly reportASX
Strategic Distribution Partnership - Additional InformationJun 28, 2022Other filingsASX
Optiscan announces Strategic Distribution Partner for ChinaJun 26, 2022Other filingsASX
OIL March 2022 Quarterly Report and Appendix 4CApr 29, 2022Quarterly reportASX
Appendix 4D and 31 December 2021 Half-year reportFeb 24, 2022Interim reportASX
OIL December 2021 Quarterly Report and Appendix 4CJan 31, 2022Quarterly reportASX
2021 AGM Chairmans Address and MD PresentationJan 20, 2022Other filingsASX
Change of Managing DirectorDec 12, 2021Other filingsASX
Completion of imaging for Melbourne Breast cancer trialNov 11, 2021Other filingsASX
OIL September 2021 Quarterly Report and Appendix 4COct 26, 2021Quarterly reportASX
Receipt of R&D Tax Incentive RebateOct 25, 2021Other filingsASX
OIL FY21 Annual Results PresentationAug 30, 2021Other filingsASX
Appendix 4E and 2021 Annual ReportAug 30, 2021Annual reportASX
OIL June 2021 Quarterly Report and Appendix 4CJul 29, 2021Quarterly reportASX
Update on seeking United States FDA approval & market entryMay 31, 2021Other filingsASX
OIL March 2021 Quarterly Report and Appendix 4CApr 28, 2021Quarterly reportASX
Appointment of New Non-executive ChairApr 18, 2021Management or board changeASX
Appendix 4D and Financial Statements - 31 December 2020Feb 25, 2021Interim reportASX
OIL breast cancer study to commence next stage - revisedFeb 8, 2021Other filingsASX
Optiscan breast cancer study to commence next stageFeb 8, 2021Other filingsASX
OIL December 2020 Quarterly Report and Appendix 4CJan 28, 2021Quarterly reportASX
Carl Zeiss Meditec AG Product OrdersJan 12, 2021Other filingsASX
Appointment of Taiwan DistributorDec 15, 2020Other filingsASX
OIL 2020 AGM PresentationNov 26, 2020Other filingsASX
TGA Approval for CONVIVO and Sterile Sheath In AustraliaNov 9, 2020Other filingsASX
OIL September 2020 Quarterly Report and Appendix 4COct 29, 2020Quarterly reportASX
US FDA Regulatory Approval updateOct 8, 2020Other filingsASX
OptiScan Capital RaisingSep 24, 2020FinancingASX
Optiscan Capital RaisingSep 21, 2020FinancingASX
Pause in TradingSep 21, 2020Trading halt or suspensionASX
Appendix 4E and 2020 Annual ReportAug 31, 2020Annual reportASX
New North American & Expanded Asia Pacific DistributionAug 28, 2020Other filingsASX
OIL June 2020 Quarterly Report and Appendix 4CJul 31, 2020Quarterly reportASX
2 X China Tender Success for FIVE2 (ViewnVivo)Jul 27, 2020Other filingsASX
Government grant to support Melbourne Dental School TrialJul 19, 2020Other filingsASX
Achievement of Final Milestone in Carl Zeiss AgreementMay 4, 2020Other filingsASX
OIL March 2020 Quarterly Report and Appendix 4CApr 30, 2020Quarterly reportASX
Corporate UpdateMar 19, 2020Other filingsASX
Appendix 4D and Financial Statements - 31 December 2019Feb 28, 2020Interim reportASX
Corporate Update - January 2020Jan 30, 2020Other filingsASX
Appointment of Second China DistributorDec 5, 2019Other filingsASX
2019 AGM PresentationNov 27, 2019Other filingsASX
Optiscan Market UpdateNov 24, 2019Other filingsASX
OIL initiates FDA feedback for Oral Cancer 510(k) submissionNov 3, 2019Other filingsASX
Appointment of new China DistributorOct 15, 2019Other filingsASX
Leading Aus & US Hospital Collaboration to trial OIL deviceSep 23, 2019Other filingsASX
Appendix 4E and 2019 Annual ReportAug 30, 2019Annual reportASX
Optiscan System Approved for Prestigious Cancer Centre TrialAug 21, 2019Other filingsASX
Investor Presentation - June 2019Jun 14, 2019Other filingsASX
Optiscan Secures Strong Support in $1.70 M Capital RaisingJun 13, 2019FinancingASX
OptiScan March 2019 PresentationMar 13, 2019Other filingsASX
Appendix 4D and Financial Statements - 31 Dec 2018Feb 28, 2019Interim reportASX
Collaboration Agreement with Summit Biomedical Imaging LLCFeb 26, 2019Other filingsASX
OptiScan technology used in research at major cancer centreFeb 25, 2019Other filingsASX
Reinstatement to Official QuotationNov 6, 2018Trading halt or suspensionASX
ZEISS achieves another milestone on regulatory pathwayNov 6, 2018Other filingsASX
Suspension from Official QuotationNov 1, 2018Trading halt or suspensionASX
Clinical Trial - Assessment of Breast Cancer MarginOct 14, 2018Other filingsASX
Appendix 4E and 2018 Annual ReportAug 31, 2018Annual reportASX
Market UpdateJun 13, 2018Other filingsASX
ZEISS CONVIVO and Appointment of Interim Executive ChairmanMay 31, 2018Management or board changeASX
Appendix 4D and Financial Statements - 31 Dec 2017Feb 28, 2018Interim reportASX
Update on CEO Recruitment and Interim ManagementFeb 15, 2018Other filingsASX
Market Update - Resignation of CEOJan 22, 2018Management or board changeASX
ViewnVivo installed for evaluation at Stanford UniversityNov 16, 2017Other filingsASX
First Sales of ViewnVivo in the Chinese MarketNov 12, 2017Other filingsASX
Zeiss/Optiscan collaboration unveils ConvivoOct 9, 2017Other filingsASX
Share Purchase Plan and Placement CompletionOct 3, 2017FinancingASX
Carl Zeiss Meditec to unveil in vivo Digital Biopsy ToolSep 20, 2017Other filingsASX
An update from the ChairmanSep 12, 2017Other filingsASX
Preliminary Final Report - Appendix 4EAug 29, 2017ResultsASX
Share Placement and Underwritten Share Purchase PlanAug 23, 2017FinancingASX
ViewnVivo UpdateAug 16, 2017Other filingsASX
Investor Presentation - July 2017Jul 3, 2017Other filingsASX
Optiscan Appoints Exclusive North American DistributorJun 28, 2017Other filingsASX
Amended Appendix 4DMar 8, 2017Interim reportASX
Appendix 4D and Financial Statements - 31 Dec 2016Feb 28, 2017Interim reportASX
Cleansing ProspectusDec 27, 2016Offer documentASX
Prospectus - Share and Option Issues approved at AGMDec 21, 2016Offer documentASX
Share PlacementDec 20, 2016FinancingASX
Pre-clinical research product launchNov 22, 2016Other filingsASX
Receipt of R&D tax rebate incentiveNov 8, 2016Other filingsASX
Preliminary Final Report- Appendix 4EAug 31, 2016ResultsASX
Update on cooperation with Carl Zeiss MeditecAug 21, 2016Other filingsASX
Reinstatement to Official Quotation - 22 August 2016Aug 19, 2016Trading halt or suspensionASX
Shares issued 19 August 2016 and request for reinstatementAug 19, 2016Other filingsASX
NEW FUNDING FOR OPTISCANMar 30, 2016Other filingsASX
Zeiss Neurosurgery Purchase OrderMar 30, 2016Other filingsASX
Shareholder Update June 2012Mar 30, 2016Other filingsASX
$2M Funding from Bergen Global Opportunity Fund, LPMar 30, 2016Other filingsASX
Zeiss Milestones ActualisedMar 30, 2016Other filingsASX
Update, Capital Raise and Appendix 4EMar 30, 2016ResultsASX
Trading Halt RequestMar 30, 2016Trading halt or suspensionASX
New Funding Facility and Operations UpdateMar 30, 2016Operations updateASX
Optiscan in Clinical Study at St Vincents SydneyMar 30, 2016Other filingsASX
Optiscan Receives R&D Tax Incentive, Loan RepaidFeb 11, 2016Other filingsASX
Board Changes and Funding UpdateFeb 10, 2016Other filingsASX
CellLIVE UpdateFeb 10, 2016Other filingsASX
Optiscan Zeiss Collaboration UpdateFeb 10, 2016Other filingsASX
Global Launch of CellLIVe in Hawaii, USAFeb 10, 2016Other filingsASX
Optiscan Appendix 4E and Financial StatementsFeb 10, 2016ResultsASX
Board Changes at OptiscanFeb 10, 2016Other filingsASX
Non-Renounceable IssueFeb 10, 2016Other filingsASX
Funding and UpdateFeb 10, 2016Other filingsASX
Half Yearly Report and AccountsFeb 10, 2016Interim reportASX
Major Milestone RecognisedFeb 10, 2016Other filingsASX
Major Step in Zeiss Product DevelopmentFeb 10, 2016Other filingsASX
New Global Supply AgreementFeb 10, 2016Other filingsASX
New US Patent for OptiscanFeb 10, 2016Other filingsASX
March Quarter 2010 UpdateFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Optiscan Imaging Limited’s releases

Common shares
1,045,612,380
Fully diluted
1,045,612,380

Fully diluted

LineShares
Common shares1,045,612,380

Share count over time

CountShares
Nov 22, 20261,045,612,380

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Camile FarahChief Executive Officer · Since at least Nov 5, 2026
Darius OoiChief Financial Officer · Since at least Nov 4, 2026
Elissa HansenCompany Secretary · Since at least Nov 5, 2026
Hiran JayetilekeManufacturing Manager · Nov 4, 2026 – Nov 7, 2026 · Past
Jessica WardDirector of Clinical and Regulatory Affairs · Since at least Nov 4, 2026
Karen BorgNon-Executive Director · Since at least Nov 5, 2026
Kaylene DawsonGeneral Counsel · Nov 4, 2026 – Nov 7, 2026 · Past
Lindsay BussauApplications & Customer Support Manager · Nov 4, 2026 – Nov 7, 2026 · Past
Paul UnwinSupply Chain, Service and Infrastructure Manager · Nov 4, 2026 – Nov 7, 2026 · Past
Peter PavlicekProject Manager · Nov 4, 2026 – Nov 7, 2026 · Past
All 17 people
PersonSeat
Robert CookeNon-Executive Chairman · Since at least Nov 5, 2026
Robert SayeghDirector of Strategy & Portfolio Integration · Since at least Nov 7, 2026
Ron SongNon-Executive Director · Since at least Nov 5, 2026
Russell LowNon-Executive Director · Since at least Nov 5, 2026
Sanchitha FernandoChief Technology Officer · Since at least Nov 4, 2026
Sean GardinerNon-Executive Director · Since at least Nov 5, 2026
Yameena CossinsQuality Assurance Manager · Nov 4, 2026 – Nov 7, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Optiscan Imaging Limited.